TY - JOUR
T1 - Long term safety of GnRH agonist therapy in precocious puberty
T2 - An evaluation of reproductive function, bone density and body composition
AU - Lee, Peter
AU - Silverman, Lawrence A.
N1 - Funding Information:
Publication of this paper was supported by the Centre of excellence for systems and services of intelligent transport II., ITMS 26220120050 supported by the Research & Development Operational Programme funded by the EDF R and Institutional research project „ The impact of Mobility Packa ges on hauliers in road transport “, I -19-001-07, University of Zilina in Zilina, Faculty PEDAS.
PY - 2007/6
Y1 - 2007/6
N2 - While the use of GnRH agonists is viewed as a very safe therapy for central precocious puberty, outcome safety issues after therapy concerning completion of puberty, reproductive function, bone mineral density and body composition need to be further documented. This review article raises no significant concerning abnormailities of the recovery of the pubertal reproductive axis, evidence of normal fertility, bone density or body composition Hence, to date, such therapy continues to have a clearly positive risk:benefit ratio.
AB - While the use of GnRH agonists is viewed as a very safe therapy for central precocious puberty, outcome safety issues after therapy concerning completion of puberty, reproductive function, bone mineral density and body composition need to be further documented. This review article raises no significant concerning abnormailities of the recovery of the pubertal reproductive axis, evidence of normal fertility, bone density or body composition Hence, to date, such therapy continues to have a clearly positive risk:benefit ratio.
UR - http://www.scopus.com/inward/record.url?scp=34250214192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250214192&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:34250214192
SN - 1565-4753
VL - 4
SP - 300
EP - 305
JO - Pediatric Endocrinology Reviews
JF - Pediatric Endocrinology Reviews
IS - SUPPL. 3
ER -
